Healthcare Contract Manufacturing Market Size & Growth Forecast 2027–2036, By Segments (Type, End-use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Healthcare Contract Manufacturing Market size was more than USD 257.6 billion in 2026 and is set to grow at a 11.31% CAGR between 2027 and 2036, reaching USD 752.12 billion by 2036. The industry revenue for 2027 is estimated at USD 282.12 billion.
Get more details on this report
Request Free Sample ReportHealthcare Contract Manufacturing Market Intelligence Snapshot
Regional Market Dynamics
- Asia Pacific leads with 41.02% share due to dense contract manufacturer base, scalable production capacity, and cost-efficient operations supporting high-volume pharmaceutical and medical product outsourcing.
- Growth is driven by rising outsourcing from pharma and medtech firms, expanding healthcare demand, and improving industrial infrastructure enabling flexible, faster manufacturing partnerships, supporting 10.96% CAGR across the region.
Segment Momentum
- Pharmaceutical contract manufacturing held a 75.19% share in 2026, driven by large-scale outsourced drug production, recurring manufacturing demand, and established partnerships supporting formulation, production, and packaging needs.
- Medical Device Companies are the fastest-growing end-use segment as they increasingly seek scalable, flexible manufacturing partners capable of supporting specialized products and evolving production requirements.
Market Expansion Drivers
- Expanding biologics and biosimilars outsourcing driving large-scale contract manufacturing demand.
- Increasing regulatory complexity pushing pharmaceutical firms toward compliant contract manufacturing partners.
- Rising outsourcing of non-core pharmaceutical production improving cost efficiency and scalability.
Leading Market Participants
- Major companies in the healthcare contract manufacturing market include Thermo Fisher Scientific Inc. (United States), Lonza Group AG (Switzerland), Catalent, Inc. (United States), Samsung Biologics Co., Ltd. (South Korea), WuXi AppTec Co., Ltd. (China), Recipharm AB (Sweden), Boehringer Ingelheim International GmbH (Germany), FUJIFILM Diosynth Biotechnologies U.S.A., Inc. (United States), Flex Ltd. (Singapore), Integer Holdings Corporation (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 257.6 billion
- 2027 Estimated Market Size: USD 282.12 billion.
- Projected Market Size: USD 752.12 billion by 2036
- Growth Forecast: 11.31% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: Asia Pacific
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Pharmaceutical (Type) | Pharmaceutical & Biopharmaceutical Companies (End-use)
- Emerging Opportunity Segment: Medical Devices (Type) | Medical Device Companies (End-use)
Market Growth Drivers and Industry Trends
Expanding biologics and biosimilars outsourcing driving large-scale contract manufacturing demand
The healthcare contract manufacturing market is benefiting from the expanding outsourcing of biologics and biosimilars, as these products require specialized manufacturing capabilities, sophisticated production processes, and stringent quality controls. Pharmaceutical companies increasingly rely on experienced manufacturing partners to access advanced production infrastructure and technical expertise without making extensive investments in internal capacity. This outsourcing model supports the development and commercial production of complex therapies while enabling manufacturers to accommodate changing production requirements and specialized biologics workflows.
Increasing regulatory complexity pushing pharmaceutical firms toward compliant contract manufacturing partners
Increasing regulatory complexity is encouraging pharmaceutical companies to work with specialized partners capable of maintaining rigorous quality, documentation, and compliance requirements. The healthcare contract manufacturing market will gain from this shift as contract manufacturers provide established quality systems and manufacturing processes designed to meet stringent pharmaceutical standards. By transferring complex compliance responsibilities to experienced providers, drug manufacturers can reduce operational burdens while maintaining consistent production practices and addressing evolving regulatory expectations.
Rising outsourcing of non-core pharmaceutical production improving cost efficiency and scalability
The healthcare contract manufacturing market is being strengthened as pharmaceutical companies increasingly outsource non-core production activities to improve operational efficiency and manufacturing flexibility. External manufacturing partners allow companies to limit investment in internal production infrastructure while gaining access to established facilities, specialized capabilities, and scalable production resources. This approach enables pharmaceutical firms to adjust manufacturing capacity according to demand while directing internal resources toward higher-value activities such as drug development, commercialization, and strategic portfolio management.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Expanding biologics and biosimilars outsourcing driving large-scale contract manufacturing demand | 2.50% | High | Asia Pacific, North America | High | Mid Term |
| Increasing regulatory complexity pushing pharmaceutical firms toward compliant contract manufacturing partners | 2.30% | High | North America, Europe | High | Near Term |
| Rising outsourcing of non-core pharmaceutical production improving cost efficiency and scalability | 1.80% | High | Asia Pacific, Europe | High | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
Asia Pacific (Largest & Fastest-Growing Region)
The healthcare contract manufacturing market in Asia Pacific accounted for a 41.02% share in 2026, reflecting the region’s strong manufacturing base and expanding role in global healthcare supply chains. Growing demand for cost-efficient production, increasing pharmaceutical and medical device manufacturing capabilities, and continued investments in specialized production infrastructure are strengthening regional outsourcing activity. Contract manufacturers are also benefiting from improving technical capabilities, quality systems, and regulatory readiness, enabling them to support increasingly complex healthcare products while helping manufacturers optimize production costs and capacity.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants/Startups i Scale Low Medium High | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Precision Manufacturing FocusGermany strengthens the healthcare contract manufacturing market through advanced engineering capabilities and strict quality standards. Manufacturers in Germany invest in process optimization, automated production, and regulatory alignment to serve pharmaceutical and medical technology customers requiring consistent product quality.
France 🇫🇷
Specialized Pharmaceutical SupportFrance advances the healthcare contract manufacturing market through expertise in pharmaceutical formulation, packaging, and sterile manufacturing. Companies in France increasingly collaborate with healthcare innovators seeking specialized production capabilities and dependable regulatory compliance across multiple product categories.
Italy 🇮🇹
Flexible Manufacturing NetworksItaly supports the healthcare contract manufacturing market with diversified manufacturing networks serving pharmaceuticals and medical devices. Italian manufacturers focus on customized production services, efficient supply chain coordination, and adaptable manufacturing solutions for regional and international healthcare companies.
Japan 🇯🇵
Quality-Centric ProductionJapan focuses on highly controlled healthcare contract manufacturing for specialized pharmaceuticals and medical products. Companies in Japan emphasize manufacturing reliability, continuous process improvement, and long-term production partnerships that support stringent quality expectations across healthcare applications.
South Korea 🇰🇷
Biopharma Production ExpansionSouth Korea continues expanding healthcare contract manufacturing capabilities with strong investment in biologics and advanced pharmaceutical production. Contract manufacturers in South Korea enhance integrated development and manufacturing services while supporting international regulatory requirements and export-oriented operations.
United States 🇺🇸
Outsourcing Innovation HubThe U.S. healthcare contract manufacturing market emphasizes flexible production partnerships for biologics, medical devices, and complex pharmaceuticals. Companies in the U.S. increasingly prioritize scalable manufacturing capacity, regulatory compliance, and rapid technology transfer to support evolving healthcare product pipelines.
Segment Leadership and Growth Trends
Healthcare Contract Manufacturing Market Share (%), by Type, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportType Segment Analysis: Pharmaceutical (Largest Segment) vs Medical Devices (Fastest-Growing Segment)
The pharmaceutical segment dominated the healthcare contract manufacturing market with a 75.19% share in 2026, driven by the extensive use of external manufacturing partners for drug production, formulation, packaging, and related development activities. Pharmaceutical companies increasingly rely on specialized contract manufacturers to access technical capabilities, optimize production operations, and respond efficiently to changing manufacturing requirements. Growing outsourcing across the pharmaceutical value chain and the need for specialized production expertise continue to support the segment's leading position.
Medical devices represent the fastest-growing segment as manufacturers increasingly leverage external partners for specialized production, engineering, assembly, and quality-related capabilities. Outsourcing can help medical device developers access advanced manufacturing expertise while improving flexibility and supporting efficient commercialization. Increasing complexity in device design, demand for specialized components, and the broader preference for asset-light manufacturing strategies are encouraging greater use of contract manufacturing services across the medical device industry.
End-use Segment Analysis: Pharmaceutical & Biopharmaceutical Companies (Largest Segment) vs Medical Device Companies (Fastest-Growing Segment)
Pharmaceutical & biopharmaceutical companies represented the largest share of the healthcare contract manufacturing market at 75.19% in 2026, reflecting their extensive dependence on external partners for manufacturing activities across increasingly complex drug development pipelines. Outsourcing enables these organizations to access specialized production capabilities while supporting scalability, quality management, and operational efficiency. The expansion of biologics and other complex therapies, combined with increasing pressure to optimize manufacturing resources, continues to reinforce reliance on contract manufacturing partnerships.
Medical device companies are expanding their use of contract manufacturing as product designs become more sophisticated and production requirements increasingly demand specialized capabilities. External manufacturing partners can provide access to advanced production technologies, engineering expertise, quality systems, and scalable capacity without requiring manufacturers to develop every capability internally. Rising demand for innovative medical devices and greater emphasis on efficient commercialization are supporting stronger adoption of outsourced manufacturing models within this end-use segment.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Type | Medical Devices, Pharmaceutical | Pharmaceutical | Medical Devices |
| End-use | Medical Device Companies, Pharmaceutical & Biopharmaceutical Companies, Others | Pharmaceutical & Biopharmaceutical Companies | Medical Device Companies |
Competitive Landscape and Market Positioning
Top players in the healthcare contract manufacturing market:
1. Thermo Fisher Scientific Inc. (United States)
2. Lonza Group AG (Switzerland)
3. Catalent Inc. (United States)
4. Samsung Biologics Co. Ltd. (South Korea)
5. WuXi AppTec Co. Ltd. (China)
6. Recipharm AB (Sweden)
7. Boehringer Ingelheim International GmbH (Germany)
8. FUJIFILM Diosynth Biotechnologies U.S.A. Inc. (United States)
9. Flex Ltd. (Singapore)
10. Integer Holdings Corporation (United States)
Rising production costs are driving developers to seek regional outsourcing hubs to scale up their commercial operations. This geographical shift allows the healthcare contract manufacturing market to offer localized, compliant scaling solutions that bring therapeutic products to regional consumers much faster.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc. (United States) | |||||||
| Lonza Group AG (Switzerland) | |||||||
| Catalent Inc. (United States) | |||||||
| Samsung Biologics Co. Ltd. (South Korea) | |||||||
| WuXi AppTec Co. Ltd. (China) | |||||||
| Recipharm AB (Sweden) | |||||||
| Boehringer Ingelheim International GmbH (Germany) | |||||||
| FUJIFILM Diosynth Biotechnologies U.S.A. Inc. (United States) | |||||||
| Flex Ltd. (Singapore) | |||||||
| Integer Holdings Corporation (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Jubilant Biosys | Jan-26 | Jubilant Biosys opened a new discovery and preclinical facility in Noida, India, doubling its CRDMO chemistry capacity. The site integrates discovery-to-scale-up services, featuring pilot plants and advanced R&D labs to meet rising demand for fee-for-service contracts and improve turnaround timelines for global pharmaceutical innovators. |
| Rakuten Medical | Jan-26 | Rakuten Medical entered a strategic manufacturing partnership with LOTTE Biologics to support the production of monoclonal antibody intermediates and conjugates for its proprietary photoimmunotherapy platform. This agreement leverages LOTTE’s specialized bioconjugation capabilities to accelerate oncology drug development and clinical trial supply chains. |
| UCB | Jun-25 | UCB announced a USD 5 billion investment to establish a new biologics manufacturing facility in the United States. This strategic expansion aims to bolster global supply chain resilience, support the company’s forthcoming drug pipeline, and create significant high-skilled employment, reflecting a commitment to scaling manufacturing capacity for long-term therapeutic access. |
| Jabil Inc. | Feb-25 | Jabil Inc. completed the acquisition of Pharmaceutics International, Inc. (Pii) for USD 309 million. This transaction integrates Pii’s specialized expertise in aseptic filling, lyophilization, and oral solid dose manufacturing into Jabil’s Regulated Industries segment, expanding its end-to-end development and commercial-scale capabilities for complex medical and pharmaceutical products. |
| Lotte Biologics | Jan-25 | Lotte Biologics unveiled plans for a USD 3.4 billion biocampus in South Korea, designed to integrate development, clinical-stage production, and large-scale commercial manufacturing. This investment creates a dual-site operational network with the company’s Syracuse facility, enabling greater flexibility and scalability for global clients seeking diversified, high-capacity biopharmaceutical manufacturing solutions. |
| Novo Holdings | Dec-24 | Novo Holdings completed the USD 16.5 billion acquisition of Catalent, Inc. This transformative transaction significantly expands global fill-finish capacity and viral-vector manufacturing capabilities. By securing this infrastructure, the investment strengthens the broader industry’s ability to meet the escalating production demands for advanced biologics and complex drug delivery systems. |
| Fujifilm | Nov-24 | Fujifilm confirmed a USD 1.2 billion expansion at its North Carolina manufacturing site, adding eight large-scale mammalian cell culture bioreactors. This investment, which builds upon the company’s existing global infrastructure, increases production capacity for antibody drug substances to address the growing outsourcing needs of the biopharmaceutical sector through 2031. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Healthcare Contract Manufacturing Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Service Scope | Contract Development, Contract Manufacturing, Packaging & Labeling, Integrated Development & Manufacturing |
| Production Stage | Preclinical & Clinical-Stage Manufacturing, Commercial Manufacturing, Post-Approval Manufacturing |
| Geographic Delivery Model | Domestic Contract Manufacturing, Nearshore Contract Manufacturing, Offshore Contract Manufacturing |
Healthcare Contract Manufacturing Market — Custom
| Custom Chapter | Custom Details |
|---|---|
| Outsourcing Decision Framework by Manufacturing Function |
|
| CDMO Partner Benchmarking and Vendor Selection Matrix |
|
| Supply Chain Resilience and API Sourcing Risk Assessment |
|
Need a different cut of the data?
Request Custom ResearchWhat is the market size of healthcare contract manufacturing?
What is the anticipated CAGR of the healthcare contract manufacturing industry?
Why is biologics and biosimilars outsourcing reshaping demand in the healthcare contract manufacturing market?
How is regulatory complexity influencing partner selection in the healthcare contract manufacturing market?
Why does pharmaceutical contract manufacturing dominate the healthcare contract manufacturing market?
How are medical device companies influencing growth in the healthcare contract manufacturing market?
Why does Asia Pacific lead the healthcare contract manufacturing market in 2026?
How is Asia Pacific sustaining its fastest growth in healthcare contract manufacturing?
Which organizations are considered leaders in the healthcare contract manufacturing landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Why It Matters | Reference |
|---|---|---|
| World Health Organization (WHO) | Global health statistics, disease burden, healthcare policies | www.who.int |
| U.S. Food & Drug Administration (FDA) | Medical devices, pharmaceuticals, diagnostics, approvals | www.fda.gov |
| European Medicines Agency (EMA) | Pharmaceutical approvals and regulatory guidance in Europe | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | Disease surveillance, public health, epidemiology | www.cdc.gov |
| National Institutes of Health (NIH) | Biomedical research, clinical studies, funding | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | Biomedical databases, PubMed, genomics | www.ncbi.nlm.nih.gov |
| PubMed | Peer-reviewed biomedical literature | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | Global clinical trial registry | clinicaltrials.gov |
| International Organization for Standardization (ISO) | Medical device quality and healthcare standards | www.iso.org |
| ASTM International | Medical device testing and material standards | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | Medical devices and diagnostics industry | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | Medical device innovation and regulatory science | mdic.org |
| Biotechnology Innovation Organization (BIO) | Biotechnology industry developments | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | Global pharmaceutical industry | www.ifpma.org |
| U.S. Pharmacopeia (USP) | Drug quality standards and reference materials | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | European pharmaceutical quality standards | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | Veterinary healthcare and animal diseases | www.woah.org |
| American Hospital Association (AHA) | Hospital operations and healthcare delivery | www.aha.org |
| OECD Health | International healthcare expenditure and system statistics | www.oecd.org/health |
| World Bank Data | Healthcare expenditure and demographic indicators | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization